Why Faeth Therapeutics, Inc.’s (FTH) Stock Is Down 5.84%
As of Thursday, September 24, Faeth Therapeutics, Inc.’s FTH share price has dipped by 5.84%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company’s pipeline includes SNS-102 and SNS-103, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. The company was formerly known as Sensei Biotherapeutics, Inc. and changed its name to Faeth Therapeutics, Inc. in June 2026. The company was incorporated in 1999 and is headquartered in Rockville, Maryland.
Commentary & Analysis
Why Faeth Therapeutics, Inc.’s (FTH) Stock Is Down 8.02%
As of Thursday, September 24, Faeth Therapeutics, Inc.’s FTH share price has dipped by 8.02%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Faeth Therapeutics, Inc.’s (FTH) Stock Is Down 10.86%
As of Thursday, September 24, Faeth Therapeutics, Inc.’s FTH share price has dipped by 10.86%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Faeth Therapeutics, Inc.’s (FTH) Stock Is Down 6.14%
As of Monday, September 21, Faeth Therapeutics, Inc.’s FTH share price has dipped by 6.14%, which has investors questioning if this is right time to buy.Michael Rose
Why Faeth Therapeutics, Inc.’s (FTH) Stock Is Down 5.32%
As of Monday, September 21, Faeth Therapeutics, Inc.’s FTH share price has dipped by 5.32%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | FTH | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $723.5 | $257.9 | 41% |
|
| Shares Out (Mil) | 5.6 | 54.3 | 15% |
|
| Institutional Ownership | 90.8% | 92.9% | 59% |
|
| Float (Mil) | 18.5 | 41.4 | 28% |
|
| Beta | -0.28 | 0.95 | 3% |
|
| Avg Daily Volume (000s) | 599 | 674 | 59% |
|
| Price Change (52-week) |
210.4% | 51.5% | 98% |
|
| Growth | FTH | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | (1.0%) | (10.1%) | 39% |
|
| EPS (5yr) | 41.8% | 15.8% | 89 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (14.9%) | (15.6%) | 53% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | FTH | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($196) | ($43) | 7% |
|
| EPS (TTM) | ($82.458) | ($1.600) | 1% |
|
| Operating Cash Flow (TTM) (Mil) | ($34) | ($32) | 12% |
|
| Net Cash Flow (TTM) (Mil) | $14 | $2 | 59% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $722 | $174 | 38% |
|
| Valuation | FTH | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.18 | 2.51 | 75% |
|
| P/E | na | 19.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | FTH | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 68.9% | na |
|
| Net Margin | na | (72.5%) | na |
|
| ROA | (176.9%) | (47.7%) | 2% |
|
| ROE | (195.3%) | (54.9%) | 4% |
|
| Liabilities to Assets | 8.6% | 29.1% | 5% |
|
| F-Score | 3 | 3 | 18% |
|
Faeth Therapeutics, Inc. did not pass any screens on 9/25/2026.
